FDA
-
-
-
-
-
-
-
Cogent (COGT) Reiterated at Buy by Stifel After ASCO Presentation on Bezuclastinib
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
-
-
-
-
-
-
-
Cogent Biosciences outlines 2026 milestones for bezuclastinib drug applications
-
-
-
-
-
-
-
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
-
-
-
-
-
-
Cogent Biosciences presents KRAS inhibitor data at cancer conference
-
-
-
-
-
-
-
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Adv
-
328,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

